Literature DB >> 23280144

Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.

Baoxiang Guan1, Hao Li, Zhengduo Yang, Ashraful Hoque, Xiaochun Xu.   

Abstract

BACKGROUND: Gastroesophageal reflux is a risk factor for esophageal adenocarcinoma, and bile acid and its farnesoid X receptor (FXR) have been implicated in esophageal tumorigenesis. The authors investigated the role of FXR expression and activity in esophageal cancer initiation and growth.
METHODS: FXR expression in esophageal adenocarcinoma tissues was assessed by immunohistochemistry. Knockdown of FXR expression in esophageal cancer cells in vitro and in nude mice xenografts was suppressed by FXR small hairpin RNA (shRNA) and guggulsterone (a natural FXR inhibitor). Esophageal cancer cells were treated with bile acids to demonstrate their effects on growth-promoting genes.
RESULTS: FXR was expressed in 48 of 59 esophageal adenocarcinoma tissues (81.3%), and this overexpression was associated with higher tumor grade, larger tumor size, and lymph node metastasis; however, was inversely associated with retinoic acid receptor-β2 (RAR-β2 ) expression. Knockdown of FXR expression suppressed tumor cell growth in vitro and in nude mouse xenografts. Guggulsterone reduced the viability of esophageal cancer cells in a time-dependent and dose-dependent manner, whereas this effect was diminished after knockdown of FXR expression. Guggulsterone induced apoptosis through activation of caspase-8, caspase-9, and caspase-3 in tumor cells. FXR mediated bile acid-induced alterations of gene expression, eg, RAR-β2 and cyclooxygenase-2 (COX-2).
CONCLUSIONS: Inhibition of FXR by FXR shRNA or guggulsterone suppressed tumor cell viability and induced apoptosis in vitro, and it reduced tumor formation and growth in nude mouse xenografts. FXR also mediated bile acid-induced alterations of cell growth-related genes in esophageal cancer cells.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280144      PMCID: PMC3604152          DOI: 10.1002/cncr.27910

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

Review 1.  GUGULIPID: a natural cholesterol-lowering agent.

Authors:  Nancy L Urizar; David D Moore
Journal:  Annu Rev Nutr       Date:  2003-02-26       Impact factor: 11.848

2.  Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells.

Authors:  S Song; X C Xu
Journal:  Biochem Biophys Res Commun       Date:  2001-03-09       Impact factor: 3.575

3.  Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells.

Authors:  Ming Li; Shumei Song; Scott M Lippman; Xiao-kun Zhang; Xiaoming Liu; Reuben Lotan; Xiao-Chun Xu
Journal:  Oncogene       Date:  2002-01-17       Impact factor: 9.867

Review 4.  Nuclear receptors and lipid physiology: opening the X-files.

Authors:  A Chawla; J J Repa; R M Evans; D J Mangelsdorf
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

5.  A natural product that lowers cholesterol as an antagonist ligand for FXR.

Authors:  Nancy L Urizar; Amy B Liverman; D'Nette T Dodds; Frank Valentin Silva; Peter Ordentlich; Yingzhuo Yan; Frank J Gonzalez; Richard A Heyman; David J Mangelsdorf; David D Moore
Journal:  Science       Date:  2002-05-02       Impact factor: 47.728

6.  Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion.

Authors:  J Y Lee; K T Lee; J K Lee; K H Lee; K-T Jang; J S Heo; S H Choi; Yil Kim; J C Rhee
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

7.  The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro.

Authors:  G J S Jenkins; K Harries; S H Doak; A Wilmes; A P Griffiths; J N Baxter; J M Parry
Journal:  Carcinogenesis       Date:  2003-12-04       Impact factor: 4.944

Review 8.  Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations.

Authors:  N Barak; E D Ehrenpreis; J R Harrison; M D Sitrin
Journal:  Obes Rev       Date:  2002-02       Impact factor: 9.213

9.  Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line.

Authors:  Kshama Jaiswal; Vincent Tello; Christie Lopez-Guzman; Fiemu Nwariaku; Thomas Anthony; George A Sarosi
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

10.  Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump.

Authors:  Jisong Cui; Li Huang; Annie Zhao; Jane-L Lew; Jinghua Yu; Soumya Sahoo; Peter T Meinke; Inmaculada Royo; Fernando Pelaez; Samuel D Wright
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

View more
  33 in total

1.  Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease.

Authors:  Bi Chen; Wen-Jie You; Shan Xue; Hui Qin; Xu-Ji Zhao; Miao Zhang; Xue-Qing Liu; Shu-Yang Zhu; Han-Dong Jiang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 2.  Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.

Authors:  Vineet K Dhiman; Michael J Bolt; Kevin P White
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

3.  Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy.

Authors:  Andi Marquardt; Moh'd Mohanad Al-Dabet; Sanchita Ghosh; Shrey Kohli; Jayakumar Manoharan; Ahmed ElWakiel; Ihsan Gadi; Fabian Bock; Sumra Nazir; Hongjie Wang; Jonathan A Lindquist; Peter Paul Nawroth; Thati Madhusudhan; Peter R Mertens; Khurrum Shahzad; Berend Isermann
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

4.  Preliminary study on Emodin alleviating alpha-naphthylisothiocyanate-induced intrahepatic cholestasis by regulation of liver farnesoid X receptor pathway.

Authors:  Yan Ding; Xiao-Li Xiong; Li-Shan Zhou; Su-Qi Yan; Huan Qin; Hua-Rong Li; Ling-Ling Zhang; Peng Chen; Cong Yao; Zhi-Xia Jiang; Lei Zhao
Journal:  Int J Immunopathol Pharmacol       Date:  2016-10-05       Impact factor: 3.219

5.  Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression.

Authors:  Fei Zhong; Jing Yang; Zhu-Ting Tong; Liu-Liu Chen; Lu-Lu Fan; Fang Wang; Xia-Li Zha; Jun Li
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

Review 6.  Metastasis suppressors in breast cancers: mechanistic insights and clinical potential.

Authors:  Christopher R Bohl; Sitaram Harihar; Warren L Denning; Rahul Sharma; Danny R Welch
Journal:  J Mol Med (Berl)       Date:  2013-12-06       Impact factor: 4.599

7.  Nuclear Receptors and Lipid Sensing.

Authors:  James L Thorne; Giorgia Cioccoloni
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

8.  Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Authors:  Wen Liu; Carolyn J Vivian; Amanda E Brinker; Kelsey R Hampton; Evi Lianidou; Danny R Welch
Journal:  Cancer Microenviron       Date:  2014-06-18

9.  Amiloride and guggulsterone suppression of esophageal cancer cell growth in vitro and in nude mouse xenografts.

Authors:  Baoxiang Guan; Ashraful Hoque; Xiaochun Xu
Journal:  Front Biol (Beijing)       Date:  2014-02

10.  Differential modulation of FXR activity by chlorophacinone and ivermectin analogs.

Authors:  Chia-Wen Hsu; Jui-Hua Hsieh; Ruili Huang; Dirk Pijnenburg; Thai Khuc; Jon Hamm; Jinghua Zhao; Caitlin Lynch; Rinie van Beuningen; Xiaoqing Chang; René Houtman; Menghang Xia
Journal:  Toxicol Appl Pharmacol       Date:  2016-10-20       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.